Manufacturing commercially viable perovskite solar cells still requires appropriate low‐temperature and scalable deposition processes to be developed. While α‐phase FAPbI 3 has higher thermal stability and broader absorption than MAPbI 3 , there still is no report of a pure α‐phase FAPbI 3 perovskite film obtained by a scalable printing method. Moreover, spontaneous conversion of the α‐phase to non‐perovskite δ‐phase under ambient conditions poses a serious challenge for practical applications. Herein, a scalable and fully solution based printing method for the fabrication of pure α‐phase FAPbI 3 perovskite solar cells is reported. Through adding N ‐methyl pyrrolidone and methylammonium chloride to the dimethylformamide based precursor solution to control the crystallization, and vacuum or air‐flow assisted film drying, pure α‐FAPbI 3 phase is obtained by doctor blading. The resulting α‐FAPbI 3 film is highly stable, with no δ‐FAPbI 3 phase being formed even after keeping it in an ambient atmosphere over a period of 200 days without encapsulation. In addition, a fully solution processed PSC with a PCE of 16.1% is processed by the vacuum assisted method, and 17.8% by the air‐flow assisted method. Replacing silver with a printed carbon electrode provides a stable PCE up to 15% for the vacuum assisted and 16.4% for the air‐flow assisted method, which is the highest performance of FAPbI 3 solar cells to date. Compared with MAPbI 3 , the fully printed FAPbI 3 perovskite devices exhibit a remarkable thermal stability in humid atmospheres which makes them a promising candidate for scalable production and commercialization.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: